Related Experiment Video
Updated: Apr 1, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
Dulaglutide: A Review in Type 2 Diabetes
Celeste B Burness1, Lesley J Scott2
1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.
Summary
Dulaglutide, a weekly injectable GLP-1 receptor agonist, effectively improves glycemic control and aids weight reduction in adults with type 2 diabetes. It is generally well-tolerated, with gastrointestinal issues being the most common side effect.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) is a global health concern requiring effective therapeutic options.
- Glucagon-like peptide-1 (GLP-1) receptor agonists represent a significant class of antidiabetic agents.
- Dulaglutide offers a once-weekly subcutaneous administration for improved patient convenience.
Purpose of the Study:
- To evaluate the efficacy and tolerability of dulaglutide in adult patients with T2DM.
- To compare dulaglutide's effectiveness against other antidiabetic agents, including liraglutide, metformin, sitagliptin, exenatide, and insulin glargine.
- To assess dulaglutide's impact on glycemic control and body weight over time.
Main Methods:
- Randomized controlled trials (RCTs) were conducted in adult patients with T2DM.
- Dulaglutide was administered subcutaneously once weekly.
- Comparisons were made with once-daily liraglutide, oral metformin, oral sitagliptin, twice-daily exenatide, and once-daily insulin glargine.
Main Results:
- Dulaglutide monotherapy demonstrated non-inferiority to liraglutide and superior efficacy to metformin for glycemic control.
- Combination therapy with dulaglutide showed non-inferiority to liraglutide and superiority to sitagliptin, exenatide, and insulin glargine.
- The 1.5 mg dose of dulaglutide led to significant body weight reduction, maintained over long-term treatment.
- Dulaglutide exhibited a low risk of hypoglycemia and was generally well-tolerated, with common adverse events including nausea, vomiting, and diarrhea.
Conclusions:
- Dulaglutide is an effective treatment option for improving glycemic control in adults with T2DM.
- The once-weekly injectable GLP-1 receptor agonist facilitates weight management in addition to glycemic control.
- Dulaglutide presents a favorable safety profile, making it a valuable therapeutic choice for T2DM management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
957
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
957
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:22Diabetes Mellitus: Type 2 and Gestational
5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
959
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
959
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.6K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.6K